These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24721290)

  • 21. Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy.
    Strober BE; Poulin Y; Teller C; Wang Y; Williams DA; Goldblum OM
    J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1701-6. PubMed ID: 24422992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment.
    Taniguchi T; Noda S; Takahashi N; Yoshimura H; Mizuno K; Adachi M
    J Eur Acad Dermatol Venereol; 2013 Nov; 27(11):1444-7. PubMed ID: 22702802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
    Martyn-Simmons CL; Green L; Ash G; Groves RW; Smith CH; Barker JN
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1394-7. PubMed ID: 19573024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
    Ryan C; Kirby B; Collins P; Rogers S
    Clin Exp Dermatol; 2009 Oct; 34(7):784-8. PubMed ID: 19438535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data.
    Cassano N; Galluccio A; De Simone C; Loconsole F; Massimino SD; Plumari A; Dattola S; Puglisi Guerra A; Donato L; Cantoresi F; De Pita O; Fenizi G; Altamura V; Congedo M; Pellicano R; Vena GA
    J Biol Regul Homeost Agents; 2008; 22(4):233-7. PubMed ID: 19036225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up.
    Menting SP; van Lümig PP; de Vries AC; van den Reek JM; van der Kleij D; de Jong EM; Spuls PI; Lecluse LL
    JAMA Dermatol; 2014 Feb; 150(2):130-6. PubMed ID: 24352354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis of the cost effectiveness of home-based phototherapy with narrow-band UV-B radiation compared with biological drugs for the treatment of moderate to severe psoriasis].
    Vañó-Galván S; Gárate MT; Fleta-Asín B; Hidalgo A; Fernández-Guarino M; Bermejo T; Jaén P
    Actas Dermosifiliogr; 2012 Mar; 103(2):127-37. PubMed ID: 22036021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.
    Mahil SK; Arkir Z; Richards G; Lewis CM; Barker JN; Smith CH
    Br J Dermatol; 2013 Aug; 169(2):306-13. PubMed ID: 23550925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
    Ortonne JP; Chimenti S; Reich K; Gniadecki R; Sprøgel P; Unnebrink K; Kupper H; Goldblum O; Thaçi D
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1012-20. PubMed ID: 21214631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre.
    Warren RB; Brown BC; Lavery D; Griffiths CE
    Br J Dermatol; 2010 Oct; 163(4):859-62. PubMed ID: 20716225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
    Menter A; Tyring SK; Gordon K; Kimball AB; Leonardi CL; Langley RG; Strober BE; Kaul M; Gu Y; Okun M; Papp K
    J Am Acad Dermatol; 2008 Jan; 58(1):106-15. PubMed ID: 17936411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
    Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis.
    Takahashi H; Tsuji H; Ishida-Yamamoto A; Iizuka H
    J Dermatol; 2013 Jan; 40(1):39-42. PubMed ID: 23039179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.
    Menter A; Augustin M; Signorovitch J; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani P
    J Am Acad Dermatol; 2010 May; 62(5):812-8. PubMed ID: 20219265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients.
    Wolf P; Hofer A; Weger W; Posch-Fabian T; Gruber-Wackernagel A; Legat FJ
    Photodermatol Photoimmunol Photomed; 2011 Aug; 27(4):186-9. PubMed ID: 21729166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation.
    Di Lernia V; Bianchi L; Guerriero C; Stingeni L; Gisondi P; Filoni A; Guarneri C; Belloni Fortina A; Lasagni C; Simonetti O; Neri I; Zangrilli A; Moretta G; Hansel K; Casanova DM; Girolomoni G; Cannavò SP; Bonamonte D
    Dermatol Ther; 2019 Nov; 32(6):e13091. PubMed ID: 31579972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.